Literature DB >> 15720474

Reduced activity of the noradrenergic system in the paraventricular nucleus at the end of pregnancy: implications for stress hyporesponsiveness.

A J Douglas1, S L Meddle, N Toschi, O J Bosch, I D Neumann.   

Abstract

We investigated whether changes in noradrenaline neurotransmission in the hypothalamus could explain the hyporesponsiveness of the hypothalamic-pituitary-adrenal (HPA) axis in late pregnancy. Noradrenaline release within the hypothalamic paraventricular nucleus in response to swim stress, as estimated by microdialysis and high-performance liquid chromatography, was lower in 20-day pregnant rats compared to virgin rats. Driving a central noradrenergic pathway using intravenous cholecystokinin increased adrenocorticotropic hormone (ACTH) secretion in virgin rats, but the response was significantly less in 16-day and 20-day pregnant rats. Thus, the activity of noradrenergic inputs to the paraventricular nucleus and the HPA axis is attenuated in late pregnancy. The sensitivity of the HPA axis to noradrenaline in pregnancy was investigated by intracerebroventricular administration of an alpha1-receptor antagonist, benoxathian, before and during exposure to swim stress. In virgin rats, benoxathian increased basal and stress-induced ACTH secretion, but in late pregnant rats the benoxathian effects were attenuated, indicating reduced sensitivity of the HPA axis to noradrenaline neurotransmission and/or the inability of the system to become disinhibited at this time. alpha1A-adrenoreceptor mRNA expression in the parvocellular and magnocellular paraventricular nucleus, measured by in situ hybridisation, was decreased in late pregnant compared to virgin rats. Additionally, blocking endogenous opioid inhibition with naloxone pretreatment restored the ACTH secretory response to cholecystokinin in pregnant rats. Thus, in late pregnancy, there is reduced noradrenergic input to the paraventricular nucleus and reduced alpha1A-receptor expression in the paraventricular nucleus, both of which may contribute to the reduced responsiveness of the HPA axis in pregnancy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15720474     DOI: 10.1111/j.1365-2826.2005.01272.x

Source DB:  PubMed          Journal:  J Neuroendocrinol        ISSN: 0953-8194            Impact factor:   3.627


  17 in total

Review 1.  The parental brain and behavior: A target for endocrine disruption.

Authors:  Matthieu Keller; Laura N Vandenberg; Thierry D Charlier
Journal:  Front Neuroendocrinol       Date:  2019-05-18       Impact factor: 8.606

2.  Brain stem catecholamines circuitry: activation by alcohol and role in the hypothalamic-pituitary-adrenal response to this drug.

Authors:  S Lee; Z Craddock; C Rivier
Journal:  J Neuroendocrinol       Date:  2011-06       Impact factor: 3.627

3.  Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine.

Authors:  Annemarie Unger; Erika Jung; Bernadette Winklbaur; Gabriele Fischer
Journal:  J Addict Dis       Date:  2010-04

4.  Pregnant rats show enhanced spatial memory, decreased anxiety, and altered levels of monoaminergic neurotransmitters.

Authors:  A H Macbeth; C Gautreaux; V N Luine
Journal:  Brain Res       Date:  2008-09-13       Impact factor: 3.252

5.  Reduced stress responsiveness in pregnancy: relationship with pattern of forebrain c-fos mRNA expression.

Authors:  Richard J Windle; Susan A Wood; Yvonne M Kershaw; Stafford L Lightman; Colin D Ingram
Journal:  Brain Res       Date:  2010-08-21       Impact factor: 3.252

Review 6.  No stress please! Mechanisms of stress hyporesponsiveness of the maternal brain.

Authors:  David A Slattery; Inga D Neumann
Journal:  J Physiol       Date:  2007-11-01       Impact factor: 5.182

7.  Rapid estradiol-17beta modulation of opioid actions on the electrical and secretory activity of rat oxytocin neurons in vivo.

Authors:  Colin H Brown; Paula J Brunton; John A Russell
Journal:  Neurochem Res       Date:  2007-10-25       Impact factor: 3.996

8.  Confounding of the Comparative Safety of Prenatal Opioid Agonist Therapy.

Authors:  Susan B Brogly; Kristen A Hahn; Sonia Hernandez Diaz; Martha Werler
Journal:  J Addict Res Ther       Date:  2015-12-31

Review 9.  Maternal Opioid Treatment: Human Experimental Research (MOTHER)--approach, issues and lessons learned.

Authors:  Hendrée E Jones; Gabriele Fischer; Sarah H Heil; Karol Kaltenbach; Peter R Martin; Mara G Coyle; Peter Selby; Susan M Stine; Kevin E O'Grady; Amelia M Arria
Journal:  Addiction       Date:  2012-11       Impact factor: 6.526

Review 10.  Treatment of opioid-dependent pregnant women: clinical and research issues.

Authors:  Hendree E Jones; Peter R Martin; Sarah H Heil; Karol Kaltenbach; Peter Selby; Mara G Coyle; Susan M Stine; Kevin E O'Grady; Amelia M Arria; Gabriele Fischer
Journal:  J Subst Abuse Treat       Date:  2008-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.